Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1989-5-19
|
pubmed:abstractText |
On the basis of in vitro studies demonstrating marked synergy between mitoxantrone and high-dose cytosine arabinoside (ara-C) (HiDAC) against L5178Y murine leukemia and clinical studies showing usefulness of the combination in patients with refractory acute myeloid leukemia, a phase I study was initiated to find tolerable doses for use in patients with refractory solid tumors. Initial dose levels were mitoxantrone 2 mg/m2 infused over 30 minutes, followed by high-dose ara-C 750 mg/m2 infused over 3 hours repeated once at 24 hours (total dose 4 mg/m2 mitoxantrone and 1,500 mg/m2 HiDAC per 2-day course), with planned subsequent escalation of mitoxantrone. Moderate-to-severe myelosuppression, however, required sequential dose reduction of both agents. Nonhematologic toxicity was restricted to manageable nausea and vomiting in one-half the patients and a single episode of transient delirium of uncertain etiology. No responses were observed in 23 heavily pretreated patients with a wide variety of malignancies. On the basis of this study, doses of 187-375 mg/m2 ara-C given every 24 hours for two doses following mitoxantrone 1 mg/m2 every 24 hours for two doses would be tolerated by most patients with subsequent dose escalation in some as allowed by myelosuppression.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0098-1532
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
159-63
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:2704336-Adult,
pubmed-meshheading:2704336-Aged,
pubmed-meshheading:2704336-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2704336-Bone Marrow,
pubmed-meshheading:2704336-Cytarabine,
pubmed-meshheading:2704336-Drug Evaluation,
pubmed-meshheading:2704336-Humans,
pubmed-meshheading:2704336-Middle Aged,
pubmed-meshheading:2704336-Mitoxantrone,
pubmed-meshheading:2704336-Neoplasms
|
pubmed:year |
1989
|
pubmed:articleTitle |
Mitoxantrone and high-dose ara-C in refractory malignancies: a phase I trial.
|
pubmed:affiliation |
Cancer Center of Wake Forest University, Winston-Salem, North Carolina.
|
pubmed:publicationType |
Journal Article
|